Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
about
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitisLong-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.Diagnosis and management of ankylosing spondylitis.Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabProgression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE studyEtanercept in the treatment of recalcitrant enteropathic arthritis: a case report.Ankylosing spondylitis: recent breakthroughs in diagnosis and treatmentDevelopments and current pharmacotherapeutic recommendations for ankylosing spondylitis.Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy.Vertebral endplate signal changes (Modic change): a systematic literature review of prevalence and association with non-specific low back pain.Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.Update on the use of etanercept across a spectrum of rheumatoid disorders.Inflammatory arthritis: an overview for primary care physicians.Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Etanercept: efficacy and safety for approved indications.Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population.Etanercept for treating axial spondyloarthritis.The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study.Adalimumab for the treatment of ankylosing spondylitis.Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis.Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients.Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers."Better but not best": a qualitative exploration of the experiences of occupational gain for people with inflammatory arthritis receiving anti-TNFα treatment.Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.
P2860
Q21195369-DD2A9440-0579-427C-94D4-09E86B655D65Q33766318-33FF6241-D4C4-4411-AD7E-3D304BDD86C3Q33990812-8815B6E1-52B1-4BA9-85E8-6BA9EDF885C7Q35039166-1D53B61B-1E30-400D-8274-717A003EC33DQ35759171-7055BA23-519C-4043-BE66-034BB566317EQ35954535-2A752B9C-3D97-4132-9DC8-4DB3907378A3Q36020178-F3923102-F08E-4262-BE1A-24F3C467312FQ36099077-FF0F92C2-46EF-4252-90D6-C8905910157BQ36143588-0F65D777-26BB-43D0-8C26-05151B9A339FQ36458447-845FC920-8A86-4235-BA1B-7FE12D38518AQ36847326-C7A90C87-6D14-4FDE-820F-EFDEF4CFF7D1Q36966051-EBE89D11-21F8-4E8E-AD1D-CFF3F8815620Q36973337-E57BCAAF-D867-4900-A3B2-DF30C6CE1464Q37172795-5A3EC361-83D5-42FD-B1BB-5D5B28F20555Q37290628-48220E32-F916-4524-A0C0-C80F74E31326Q37427257-1F67A497-29BD-4791-9A29-77BA071BB0A5Q37606758-F1E9D30E-8376-4296-97ED-95CBC96FE2D3Q37729028-307FF6CB-1069-4E94-AC00-60EA6E6F17E2Q37954714-48DC8A84-DB6B-4420-BD54-A2A5B888B0C5Q38081733-F3A09C2F-8197-47A9-ABC1-C8DF4278F445Q38691419-DD1C8346-40D0-452B-826B-AF311055E7B5Q41396084-E52F4C25-BA4A-4B77-9B31-E18335231112Q42377151-D7747D1F-22B8-4C53-94BC-03D01D09285EQ42616837-03983618-2EB7-4838-8475-2B2C424A3E97Q42670750-66F78CF6-2A55-47B8-928D-7208A3D342BBQ44397466-9AF7D107-3A97-4104-92C9-1CC380D099EDQ44659462-04FD2F80-0847-40A7-88D6-443CC51066C1Q52652457-54BC94D9-C487-4511-BB13-98E47B7F3256Q53116508-3FEA286D-2653-4654-8AAE-3152FFA1EC38
P2860
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Outcome of patients with activ ...... gnetic resonance imaging data.
@ast
Outcome of patients with activ ...... gnetic resonance imaging data.
@en
type
label
Outcome of patients with activ ...... gnetic resonance imaging data.
@ast
Outcome of patients with activ ...... gnetic resonance imaging data.
@en
prefLabel
Outcome of patients with activ ...... gnetic resonance imaging data.
@ast
Outcome of patients with activ ...... gnetic resonance imaging data.
@en
P2093
P356
P1476
Outcome of patients with activ ...... gnetic resonance imaging data.
@en
P2093
Baraliakos X
Rudwaleit M
Sörensen H
P304
P356
10.1002/ART.21588
P577
2005-12-01T00:00:00Z